THE SCIENTIFIC DISCOURSE ON THE CONTEMPORARY PHARMACOTHERAPEUTIC ARMAMENTARIUM OF DUCHENNE MUSCULAR DYSTROPHY: AN INTEGRATIVE ANALYSIS OF THE PHARMACOLOGICAL CLASSIFICATION OF THERAPEUTIC AGENTS, MOLECULAR PHARMACOLOGY, PHARMACODYNAMIC AND PHARMACOKINETIC

Abstract

Duchenne muscular dystrophy (DMD) constitutes a paradigmatic X-linked neuromuscular disorder characterized by pathogenic alterations in the DMD gene, disruption of dystrophin expression, progressive sarcolemmal instability, chronic myofiber degeneration, persistent inflammatory remodeling, impaired regenerative capacity, and inexorable deterioration of skeletal, respiratory, and cardiac muscle function. The contemporary pharmacotherapeutic armamentarium of DMD has undergone substantial expansion from predominantly glucocorticoid-based management toward an increasingly mechanistically stratified therapeutic paradigm encompassing corticosteroid pharmacotherapy, exon-skipping antisense oligonucleotides, histone deacetylase inhibition, micro-dystrophin gene replacement, and multidimensional pharmacological management of disease-associated cardiopulmonary, skeletal, endocrine, and functional complications. This scientific discourse provides an integrative pharmacological appraisal of currently established and emerging therapeutic modalities, emphasizing therapeutic classification, molecular mechanisms of action, pharmacodynamic determinants, pharmacokinetic characteristics, genotype-dependent treatment selection, adverse drug reactions, toxicological liabilities, pharmacological interactions, and comprehensive pharmacosafety considerations. Glucocorticoids remain fundamental components of DMD pharmacotherapy because of their clinically meaningful effects on muscle strength, motor performance, ambulation, and pulmonary function. Prednisone/prednisolone and deflazacort exert pleiotropic genomic and non-genomic corticosteroid effects through glucocorticoid-receptor signaling, modulating transcriptional networks involved in inflammation, immune activation, muscle homeostasis, and tissue remodeling. Vamorolone represents a pharmacologically distinctive corticosteroid derivative designed to retain glucocorticoid-mediated therapeutic activity while modifying receptor-dependent transactivation and transrepression profiles, thereby potentially altering the conventional corticosteroid toxicity spectrum. Nevertheless, chronic corticosteroid exposure necessitates systematic surveillance for growth impairment, weight gain, behavioral and metabolic abnormalities, hypertension, cataracts, osteoporosis, infection susceptibility, and hypothalamic–pituitary–adrenal axis suppression, rendering individualized dose optimization and adrenal-stress management integral components of pharmacosafety. Molecularly targeted exon-skipping therapies represent a genotype-dependent pharmacological strategy designed to manipulate pre-mRNA splicing and restore the translational reading frame of selected DMD transcripts. Eteplirsen, golodirsen, viltolarsen, and casimersen are phosphorodiamidate morpholino oligomer or related antisense oligonucleotide therapeutics directed against specific exons, respectively enabling exon 51, exon 53, or exon 45 skipping in genetically eligible patients. Their pharmacodynamic objective is the induction of dystrophin production through sequence-specific hybridization with dystrophin pre-mRNA. Their pharmacokinetic behavior is characterized by distribution to tissues, intracellular uptake, metabolic stability relative to conventional small molecules, and predominantly non-CYP-mediated elimination pathways. Pharmacovigilance nevertheless remains essential, particularly regarding renal safety, infusion-related reactions, hypersensitivity, hepatic or laboratory abnormalities, and the uncertainty associated with surrogate biomarker-mediated therapeutic assessment. Gene-replacement therapy has introduced a fundamentally different pharmacological modality through systemic delivery of a recombinant adeno-associated virus vector encoding a micro-dystrophin transgene. Delandistrogene moxeparvovec-rokl is intended to facilitate expression of a functional micro-dystrophin protein within skeletal and cardiac muscle, thereby addressing the underlying protein-deficiency phenotype rather than merely modifying downstream pathophysiology. Its pharmacological complexity encompasses vector biodistribution, cellular transduction, transgene expression, pre-existing anti-vector immunity, complement activation, hepatotoxicity, thrombocytopenia, and potentially severe immune-mediated adverse events. Consequently, patient selection, baseline serological assessment, corticosteroid immunomodulation, hepatic monitoring, and long-term pharmacovigilance constitute essential elements of responsible gene-therapy deployment. Givinostat, an orally administered histone deacetylase inhibitor, further expands the mechanistic spectrum of DMD pharmacotherapy by modulating epigenetic and transcriptional processes implicated in muscle pathology, inflammation, fibrosis, and regenerative dysfunction. Its pharmacodynamic effects are therefore conceptually distinct from corticosteroid receptor signaling, exon-specific RNA modulation, and gene replacement. Monitoring of hematological parameters, lipid metabolism, hepatic function, gastrointestinal tolerability, and other clinically relevant laboratory variables is necessary to mitigate treatment-associated toxicity. Beyond disease-modifying therapy, comprehensive DMD pharmacotherapy requires coordinated management of cardiomyopathy, respiratory insufficiency, osteoporosis, endocrine consequences, pain, contractures, and other secondary complications. Renin–angiotensin-system inhibitors, mineralocorticoid-receptor antagonists, β-adrenergic blockers, diuretics, and other cardiovascular agents may be incorporated according to individualized cardiac phenotype and guideline-directed indications, while bone-directed interventions and nutritional/endocrine therapies address corticosteroid-associated and disease-related skeletal vulnerability. Respiratory pharmacotherapy remains predominantly complication-oriented rather than disease-modifying. The contemporary DMD pharmacotherapy represents an increasingly sophisticated convergence of molecular genetics, RNA therapeutics, epigenetic pharmacology, gene therapy, immunopharmacology, and conventional clinical pharmacology. Optimal therapeutic decision-making requires integration of genotype, age, ambulatory status, disease stage, organ-system involvement, pharmacokinetic variability, treatment response, and cumulative toxicity. The emerging paradigm consequently extends beyond efficacy-centered prescribing toward precision pharmacotherapy, longitudinal pharmacovigilance, individualized benefit–risk assessment, and proactive pharmacosafety optimization throughout the lifelong clinical trajectory of DMD.